Effects of Therapeutics on Cell Migration

Overview

Myelodysplastic syndrome (MDS) is a group of cancers in which stem cells in the bone marrow have a clonal advantage and cause irregular maturation of blood cells. Dysplastic cells cannot migrate from the bone marrow to the blood. HL-60 cells, a cell line of immature neutrophils, were transduced with a lentivirus, causing miRNA-378 knockdown. This miRNA was chosen since it was found to be under-expressed in MDS. These cells, called “Zip” cells, are found to be an accurate model for MDS in the lab due to their defects in migration. HL-60 cells were additionally transduced with a random vector, “Scr” cells, to act as a control to the lentivirus. The cell model was used to test for therapeutics that could alleviate the MDS phenotype. LB-100, a PP2A inhibitor, was chosen to asses this problem since PP2A inhibits the AKT pathway which is under-expressed in MDS. Therefore, by inhibiting the inhibitor of the AKT pathway, we hoped to activate it. HL-60, Scr, and Zip cells were incubated overnight with and without LB-100. Then, a migration experiment was performed with a trans-well plate. A significant increase was found in HL-60 and Scr migration due to LB-100 (p=0.009 and p=0.012, respectively). However, there was no significant increase in Zip migration (p=0.729). Since LB-100 did not significantly reverse the MDS phenotype, it would not be an effective drug for treatment. One possibility for this result was that the AKT pathway was activated; however, a different pathway downstream was also affected. The experiment must be repeated in order to confirm these results.

Competition history

• ISEF 2020 Cellular and Molecular Biology · Entry CELL036

Resources

• ISEF abstract page ↗

Related projects

Closest projects by meaning, across every fair and year in the corpus.